Search results
Results from the WOW.Com Content Network
Progeroid syndromes are a group of diseases that cause individuals to age faster than usual, leading to them appearing older than they actually are. People born with progeria typically live until their mid- to late-teens or early twenties. [9] [10] Severe cardiovascular complications usually develop by puberty, later on resulting in death.
A new drug increased the lifespans of mice by almost 25%, decreased deaths related to cancer and other diseases, igniting hope for slowing aging in humans. New drug helps fight typical signs of ...
Studies have shown that a GLP-1 drug, exenatide, sufficiently crosses the blood-brain barrier in rodent models of Parkinson’s disease, leading to improvements in motor performance, behavior ...
Ladostigil (developmental code name TV-3326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders like Alzheimer's disease, Lewy body disease, and Parkinson's disease. [1] [2] It was developed from structural modification of rasagiline. [3]
All metabolites are less active than the parental drug or inactive altogether. The human elimination half-life is estimated to be 63 to 68 hours in patients with Parkinson's disease and 79 to 115 hours in patients with pituitary tumors. Average elimination half-life is 80 hours. The metabolism of Cabergoline is mediated by unidentified enzymes ...
Data from a small clinical trial published on Tuesday showed that a drug from the GLP-1 receptor agonist class known for weight loss slowed the loss of brain volume in people with mild Alzheimer's ...
The drug is used to treat Lambert–Eaton myasthenic syndrome (LEMS), which is a rare neuromuscular disorder characterized by muscle weakness of the limbs, affecting about 3.4 per million people. In December 2015, Catalyst submitted its new drug application to the FDA, [ 14 ] and in February 2016 the FDA refused to accept it, on the basis that ...
Researchers have found that a novel drug molecule may fight the development of early-onset Parkinson’s disease in younger people. The new compound, BIO-2007817, is from the family of ...